Findings

What do systematic reviews say?

2 questions · 2 findings · 2 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 2 · 100%

Weekly paclitaxel plus carboplatin vs tri‐weekly paclitaxel plus carboplatin

Overall survival (OS) · first‐line treatment of ovarian cancer

Weekly paclitaxel plus carboplatin showed no clear difference in overall survival (OS) compared with tri‐weekly paclitaxel plus carboplatin (high certainty).

1 finding from 1 review

Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
HR 0.92 [0.79, 1.06]
4 studies · 3699 participants
High

Topotecon+Carboplatin+Paclitaxel vs Carboplatin+Paclitaxel

Overall Survivalclinical observation · patients with ovarian cancer

Topotecon+Carboplatin+Paclitaxel showed no clear difference in overall Survivalclinical observation compared with carboplatin+Paclitaxel (high certainty).

1 finding from 1 review

Topotecan for ovarian cancer 2008 · Cochrane Headline outcomes only
HR 1.02 [0.97, 1.06]
2 studies · 1998 participants
High